BioTime (NYSEAMERICAN:BTX) released its earnings results on Thursday. The biotechnology company reported ($0.07) earnings per share for the quarter, hitting the Zacks’ consensus estimate of ($0.07), Morningstar.com reports. The firm had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.74 million.

Shares of NYSEAMERICAN BTX traded down $0.02 during trading on Friday, reaching $1.53. The company had a trading volume of 836,280 shares, compared to its average volume of 1,015,260. BioTime has a 12-month low of $0.66 and a 12-month high of $2.81.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in BTX. IndexIQ Advisors LLC lifted its holdings in shares of BioTime by 3.9% during the third quarter. IndexIQ Advisors LLC now owns 845,072 shares of the biotechnology company’s stock valued at $1,977,000 after purchasing an additional 31,918 shares in the last quarter. Vanguard Group Inc lifted its holdings in shares of BioTime by 0.6% during the third quarter. Vanguard Group Inc now owns 4,467,698 shares of the biotechnology company’s stock valued at $10,499,000 after purchasing an additional 27,841 shares in the last quarter. Destination Wealth Management bought a new position in shares of BioTime during the third quarter valued at $1,237,000. Bridgeway Capital Management Inc. lifted its holdings in shares of BioTime by 1,066.5% during the third quarter. Bridgeway Capital Management Inc. now owns 190,700 shares of the biotechnology company’s stock valued at $448,000 after purchasing an additional 174,352 shares in the last quarter. Finally, Defender Capital LLC. bought a new position in shares of BioTime during the fourth quarter valued at $3,629,000.

BTX has been the subject of several recent research reports. HC Wainwright initiated coverage on BioTime in a research report on Thursday, February 21st. They issued a “buy” rating and a $4.00 price objective for the company. Maxim Group set a $3.00 price objective on BioTime and gave the company a “buy” rating in a research report on Friday, February 15th. Dawson James initiated coverage on BioTime in a research report on Thursday, February 7th. They issued a “buy” rating for the company. Zacks Investment Research downgraded BioTime from a “buy” rating to a “hold” rating in a research report on Tuesday, January 8th. Finally, CIBC initiated coverage on BioTime in a research report on Tuesday, December 11th. They issued an “outperform” rating and a $3.50 price objective for the company. One analyst has rated the stock with a hold rating and five have given a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $3.05.

COPYRIGHT VIOLATION NOTICE: This piece was originally reported by The Cerbat Gem and is the property of of The Cerbat Gem. If you are reading this piece on another site, it was stolen and republished in violation of U.S. and international copyright & trademark laws. The original version of this piece can be read at https://www.thecerbatgem.com/2019/03/15/biotime-btx-announces-earnings-results-hits-expectations.html.

BioTime Company Profile

BioTime, Inc, a clinical-stage biotechnology company, focuses on developing and commercializing products addressing degenerative diseases based on pluripotent stem cells and HyStem cell/drug delivery platform technologies primarily in the United States and Israel. The company's lead product candidates include OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa multicenter trial for the treatment of the dry age-related macular degeneration; and Renevia, a facial aesthetics product that is in pivotal clinical trial for the treatment of HIV-associated facial lipoatrophy.

Further Reading: What is the Book Value of a Share?

Earnings History for BioTime (NYSEAMERICAN:BTX)

Receive News & Ratings for BioTime Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioTime and related companies with MarketBeat.com's FREE daily email newsletter.